Skip to main content
. 2021 Nov 14;13(22):5688. doi: 10.3390/cancers13225688

Table 4.

Correlation between the extent of immunohistochemical PSMA expression and imaging in 68Ga-PSMA-PET/CT with regard to different metastatic sides of ATC and PDTC patients.

Immunohistochemical Analysis of ATC and PDTC Tissue Samples 1 Imaging Analysis 2
Metastatic Side No PSMA Expression PSMA-Labelling Index 1
“Low Expression”
PSMA-Labelling Index 2
“Strong Expression”
PSMA-Labelling Index 3
“Strong Expresion”
Clearly PSMA-Positive Lesions/Total Rated Lesions Discreet PSMA-Positive Lesions/Total Rated Lesions
ATC
Pulmonary/pleural metastases (n = 1) 0 0 1 0 0/2 0/2
PDTC
Cervical lymph node metastases (n = 2) 0 1 1 0 0/2 1/2
Pulmonary metastases (n = 1) 0 1 0 0 0/>10 0/>10
Local recurrence (n = 1) 0 1 0 0 0/1 0/1
Osseous metastases (n = 1) 0 0 1 0 0/>10 0/>10

1 PSMA-labelling index 1, “low expression”: weak or moderate staining intensity in <5% of the neovasculature.—weak staining intensity in >5% of the neovasculature. PSMA-labelling index 2, “strong expression”: moderate staining intensity in >5% of the neovasculature.—strong staining intensity < or >5% of the neovasculature. PSMA-labelling index 3, “strong expression”: strong staining intensity not only in the neovasculature, but also in the tumor cells. 2 For explanation refer to Table 3.